Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of CAEL-101 plus plasma cell disorder therapy in treatment-naive Mayo stage IIIb AL amyloidosis
MOH_2021-05-12_009865Phase 3Recruiting
- Sponsor
- Caelum Biosciences
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 + plasma cell disorder therapy with Placebo + plasma cell disorder therapy (2 arms). Primary endpoints: Overall survival and Safety and tolerability. Started Mar 2021; status: recruiting.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2021-05-12_009865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-12_009865.